Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of MoonLake Immunotherapeutics regarding a class action lawsuit due to alleged misleading statements about the company's drug candidate SLK and its comparison to BIMZELX [1][2]. Summary by Sections Allegations - The complaint alleges that during the class period from March 10, 2024, to September 29, 2025, the defendants made materially false and misleading statements and failed to disclose critical information regarding SLK, including: - SLK and BIMZELX share the same molecular targets, specifically the inflammatory cytokines IL-17A and IL-17F [1]. - SLK's unique Nanobody structure does not provide a superior clinical benefit compared to the traditional monoclonal structure of BIMZELX [1]. - The supposed increased tissue penetration of SLK's Nanobody structure does not translate to clinical efficacy [1]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority over monoclonal antibodies [1]. Next Steps for Shareholders - Shareholders who purchased MLTX shares during the specified class period are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [2]. - Registration allows shareholders to enroll in a portfolio monitoring software for status updates throughout the case lifecycle [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated stock prices [3].